Reuters Health published an important story, “Financial transparency skin-deep at medical journals.” Excerpts:
“Nobody is making sure that authors declare their conflicts of interest.
That has a very real potential to influence public health and corporate bottom lines, experts say, because researchers with industry ties are more likely to promote drugs and downplay side effects.
…
“At its worst, it can allow patients to have unrealistic hopes about a treatment for their conditions,” Dr. Virginia Barbour, chief editor of the journal PLoS Medicine, told Reuters Health. “And it can distort the prescribing practice of physicians.”In a review of 50 reports from the British Journal of Dermatology, a top-tier skin research journal, Reuters Health has found that authors often don’t disclose even the most glaring conflicts of interest. And editors are reluctant to do anything about it — in fact, they don’t even agree on when a conflict of interest exists.
What’s more, many journal publishers derive a substantial part of their revenue from drug ads and reprint requests from pharmaceutical companies, and there are examples of editors who moonlight as paid consultants for the industry.
“Editors probably need to be more vigilant than they are at the moment,” said Barbour, whose journal doesn’t run drug ads. “And I think that editors also need to be very aware that they themselves can be part of the competing interests.”
Opinions on other issues in news, journals, PR, advertising, marketing
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
EMBresearch
June 11, 2011 at 5:37 pmThanks for posting this important article.
Do conflicts of interest pave the way for spin of non-significant data? Does this spin affect the uptake of new medical technologies?
Dr. Wini Hayes of Hayes, Inc. discusses these concerns in a similar blog article:
http://www.hayesinc.com/hayes/2011/06/07/what%E2%80%99s-spin-got-to-do-with-it/
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like